BML Capital Management’s Tourmaline Bio TRML Stock Holding History

BML Capital Management’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-245,500	Closed	-$6.43M	–	36
2023 Q4	$6.43M	Buy	245,500 +45,500	+23%	+$911K	4.87%	5
2023 Q3	$5.62M	Hold	200,000	–	–	5.16%	7
2023 Q2	$6.08M	Buy	200,000 +7,052	+4%	+$180K	5.47%	7
2023 Q1	$3.63M	Buy	+192,948	New	+$3.18M	3.14%	13

Other funds holding TRML

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

BML Capital Management's TRML Position: Q1 2024 in Review

BML Capital Management sold out of Tourmaline Bio (TRML) in Q1 2024, closing a stake of 245,500 shares — an estimated $6.43M sold.

BML Capital Management first reported a position in TRML in Q1 2023 and held it in 4 quarters. The position peaked at $6.43M in Q4 2023. 96 funds tracked by Wall St. Rank hold TRML as of Q1 2024.

BML Capital Management reported no remaining Tourmaline Bio position as of Q1 2024 after selling out during the quarter.
BML Capital Management sold 245,500 Tourmaline Bio shares in Q1 2024, an estimated $6.43M.
BML Capital Management first reported a position in Tourmaline Bio in Q1 2023 and held it in 4 quarters.
BML Capital Management's Tourmaline Bio position peaked at $6.43M in Q4 2023.
96 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2024.

Based on BML Capital Management's 13F filing for Q1 2024, filed 23 Apr 2024.